Latest News

Page 1 of 2712345...1020...Last »

November 18, 2017

Incidence of AMD Dramatically Declining

Posted in: Latest News, Research and Developments

A recent observational study at the University of Wisconsin-Madison has found that the risk of developing age-related macular degeneration (AMD) has been dramatically lessening over three generations. After looking at follow-up data on 4,819 participants and their offspring in the Beaver Dam studies (1987-2013), Karen J. Cruickshanks, Ph.D. et al found that the incidence of
read more »

November 16, 2017

Two Trials Take First Step Toward Stem Cell Treatment for AMD

Posted in: Latest News, Research and Developments

Results from two new clinical trials have added support for the use of human embryonic stem cells as treatment for the dry form of macular degeneration. Stem cells injected into the eye appear to have replaced the missing cells damaged by the disease, with no serious side effects. One study suggests it may have even improved patients’
read more »

November 16, 2017

Seeing AI Now Available Outside of U.S.

Posted in: Latest News

We announced here in July that Microsoft had released Seeing AI,  a free app that harnesses the power of Artificial Intelligence (AI) to audibly read text, identify objects, and describe people. The app was originally available only in the United States, but it is now also in the British, Irish and Australian App stores. It is still available only for iOS devices
read more »

November 11, 2017

Brolucizimab May Be the Next Treatment Option for Wet AMD

Posted in: Latest News, Research and Developments

Swiss drugmaker Novartis has announced that their new anti-VEGF drug, brolucizumab (RTH258), is meeting expectations as a potentially more effective and longer lasting treatment for wet macular degeneration than at least one of the current options. Positive results from two Phase III studies of brolucizumab versus aflibercept (Eylea) were presented at the American Academy of
read more »

October 24, 2017

New Sub-retinal Implant For Dry AMD Entering Trials

Posted in: Latest News, Research and Developments

Alongside research to find ways of restoring vision through stem cell therapy and gene therapy, attempts are being made to restore vision electronically by means of bionic implants. In past reports, we have described the ARGUS-2, which has shown success in providing a basic pixelated sense of sight to the totally blind. Now, Pixium Vision
read more »

October 24, 2017

“I’m Visually Impaired, But . . .”

Posted in: Daily Living, Health and Nutrition, Latest News

by Dan Roberts As we age, we face a number of challenges not enjoyed by the young. It seems like every day brings another condition that makes us wonder, “Is this the Big One that’s going to do me in?” Fortunately, most of these conditions are temporary, rearing their heads only to warn us that
read more »

October 15, 2017

Some AMD Patients Still Foresee Dismal Futures

Posted in: Daily Living, Latest News, Low Vision Rehabilitation

by Dan Roberts An empirical investigation* recently published in BMC Geriatrics suggests that patients being treated for the wet form of age-related macular degeneration (wAMD) expect to be worse off than the general population, even though they expect to live as long. Specifically, they look forward to a more significant deterioration of health with age,
read more »

October 13, 2017

Headworn Video Devices Are Helping The Visually Impaired To See Better

Posted in: Daily Living, Latest News

by Dan Roberts A Comparison of Two Leading Headworn Devices. Portable electronic magnifiers have come a long way in the past decade, improving clarity of vision for thousands. A natural development for those who prefer to have their hands free has been the creation of several types of headworn video devices, the leaders in the
read more »

September 9, 2017

Lampalizumab for Dry AMD Unable to Meet Expectations in Phase III Trial

Posted in: Latest News, Research and Developments

Genentech has announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of lampalizumab. Lampalizumab, as reported here in July 2016, is an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). It was designed to inhibit Complement Factor D,
read more »

September 1, 2017

Patient Assistance Survey – The Patient Access Network Needs Your Help!

Posted in: Latest News

 The Patient Access Network (PAN) Foundation is hosting a survey about patient assistance.  The PAN Foundation is a national nonprofit organization that helps people living with life-threatening, chronic and rare diseases pay for the out-of-pocket costs of their prescription medications. Prevent Blindness has been working with PAN for some time to provide patients with education
read more »

Page 1 of 2712345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann